Rationale and design of BISTRO: A randomized controlled trial to determine whether bioimpedance spectroscopy-guided fluid management maintains residual kidney function in incident haemodialysis patients

BMC Nephrology

Volumn 18, Issue 1, 2017, Pages

  Davies, Simon J ^a,l   Caskey, Fergus J ^b   Coyle, David ^c   Lindley, Elizabeth ^c,d   MacDonald, Jamie ^e   Mitra, Sandip ^c,f   Wilkie, Martin ^c   Davenport, Andrew ^g   Farrington, Ken ^h   Dasgupta, Indranil ⁱ   Ormandy, Paula ^j   Andronis, Lazaros ^k   Solis Trapala, Ivonne ^a   Sim, Julius ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e BANGOR UNIVERSITY   (United Kingdom)

^f MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h MOUNT VERNON CANCER CENTRE   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF SALFORD   (United Kingdom)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

more..

Author keywords

Bioimpedance; Body compostion; Fluid management; Fluid status; Haemodialysis; Health economics; Residual kidney function

Indexed keywords

ADULT; ANURIA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEART FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MONTREAL COGNITIVE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; AGED; COMPLICATION; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; FEMALE; FLUID THERAPY; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MALE; METABOLIC DISORDER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; QUALITY OF LIFE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DIELECTRIC SPECTROSCOPY; FEMALE; FLUID THERAPY; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; QUALITY OF LIFE; RENAL DIALYSIS; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WATER-ELECTROLYTE IMBALANCE; YOUNG ADULT;

EID: 85018628624     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-017-0554-1     Document Type: Article

References (34)

1. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12:2158-62.
2. Termorshuizen F. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the adequacy of dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004;15:1061-70.
3. Obi Y, Rhee CM, Mathew AT, et al. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol. 2016;27(12):3758-768.
4. Merkus MP, Jager KJ, Dekker FW, et al. Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The Necosad Study Group. Am J Kidney Dis. 1997;29:584-92.
5. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671-9.
6. Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. 2009;4:1925-31.
7. Flythe JE, Curhan GC, Brunelli SM. Disentangling the ultrafiltration rate-mortality association: the respective roles of session length and weight gain. Clin J Am Soc Nephrol. 2013;8:1151-61.
8. Assimon MM, Wenger JB, Wang L, et al. Ultrafiltration rate and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2016;68:911-22.
9. Flythe JE, Kshirsagar AV, Falk RJ, et al. Associations of posthemodialysis weights above and below target weight with all-cause and cardiovascular mortality. Clin J Am Soc Nephrol. 2015;10:808-16.
10. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant. 2002;17:1814-8.
11. Dasgupta I, Farrington K, Davies SJ, et al. UK National Survey of practice patterns of fluid volume management in haemodialysis patients: a need for evidence. Blood Purif. 2016;41:324-31.
12. Davies SJ, Davenport A. The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int. 2014;86:489-96.
13. Pillon L, Piccoli A, Lowrie EG, et al. Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int. 2004;66:1266-71.
14. Paniagua R, Ventura M-J, Avila-Díaz M, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant. 2010;25:551-7.
15. Wizemann V, Wabel P, Chamney P, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009;24:1574-9.
16. Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2013;61:957-65.
17. Tan BK, Yu Z, Fang W, et al. Longitudinal bioimpedance vector plots add little value to fluid management of peritoneal dialysis patients. Kidney Int. 2016;89:487-97.
18. Moissl UM, Wabel P, Chamney PW, et al. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas. 2006;27:921-33.
19. Chazot C, Wabel P, Chamney P, et al. Importance of normohydration for the long-term survival of haemodialysis patients. Nephrol Dial Transplant. 2012;27:2404-10.
20. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L). Qual Life Res. 2011;20:1727-36.
21. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851-9.
22. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012;27:520-6.
23. Hlatky M, Boineau R, Higginbotham M, et al. A brief self-administered questionnaire to determine functional capacity (the Duke activity status index). Am J Cardiol. 1989;64:651-4.
24. Tiffin-Richards FE, Costa AS, Holschbach B, et al. The Montreal cognitive assessment (MoCA) - a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. PLoS One. 2014;9:e106700. Herholz K, ed.
25. Jansen MAM, Hart AAM, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62:1046-53.
26. Fernández-Lucas M, Teruel-Briones JL, Gomis-Couto A, et al. Maintaining residual renal function in patients on haemodialysis: 5-year experience using a progressively increasing dialysis regimen. Nefrologia. 2012;32:767-76.
27. Lin Y-F, Huang J-W, Wu M-S, et al. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton). 2009;14:59-64.
28. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11:556-64.
29. McKane W, Chandna SM, Tattersall JE, et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002;61:256-65.
30. Pruthi R, Steenkamp R, Feest T. UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses. Nephron Clin Pract. 2013;125:139-69.
31. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Stat Med. 2002;21:3317-24.
32. Brookes ST, Whitley E, Peters TJ, et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1-56.
33. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-33.
34. Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Heath. 2008;11:886-97.